Teva faces pressure from heightened generic industry competition and generic Copaxone risk.
Teva's management lowered its 2017 outlook from its previous forecast released in July as the firm succumbs to increased competitive pressure, especially in the U.S. generics market, and currency headwinds, partially tied to Venezuela. We had viewed management’s previous outlook as too optimistic, but management’s new projections, which still do not include generic competition on Copaxone in 2017, show greater weakness beyond our original expectations, stemming almost entirely from the generics ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.